Cargando…

Comparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancer

PURPOSE: The aim of this study was to compare single-agent chemotherapy with targeted therapy in initial treatment and to explore a better choice of treatment for patients aged 80 years and older with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: A retrospective chart review was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qianqian, Wang, Zhehai, Guo, Jun, Liu, Liyan, Han, Xiao, Li, Minmin, Fang, Shu, Bi, Xiang, Tang, Ning, Liu, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408957/ https://www.ncbi.nlm.nih.gov/pubmed/25945061 http://dx.doi.org/10.2147/OTT.S81837

Ejemplares similares

Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer
por: Fang, Shu, et al.
Publicado: (2014)

Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
por: Tang, Ning, et al.
Publicado: (2016)

Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer
por: Liu, Mengyao, et al.
Publicado: (2018)

Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients
por: Hu, Guofang, et al.
Publicado: (2016)

Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis
por: Tang, Ning, et al.
Publicado: (2015)

Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts
por: Tang, Ning, et al.
Publicado: (2016)

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
por: Yin, Yong-Mei, et al.
Publicado: (2010)

Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer
por: Li, Minmin, et al.
Publicado: (2014)

Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer
por: Riccardi, Ferdinando, et al.
Publicado: (2010)

Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice
por: Liang, Yi-Hsin, et al.
Publicado: (2016)

The Efficacy of Combining Antiangiogenic Agents with Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer Who Failed First-Line Chemotherapy: A Systematic Review and Meta-Analysis
por: Sheng, Jin, et al.
Publicado: (2015)

Oncologic Outcome and Efficacy of Chemotherapy in Colorectal Cancer Patients Aged 80 Years or Older
por: Liu, Wenting, et al.
Publicado: (2020)

Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
por: Sun, Sheng-Jie, et al.
Publicado: (2022)

A retrospective cohort study on the efficacy and safety for combination therapy of immunotherapy, targeted agent, and chemotherapy versus immunochemotherapy or chemotherapy alone in the first-line treatment of advanced biliary tract carcinoma
por: Zeng, Jie, et al.
Publicado: (2023)

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
por: García-Alfonso, Pilar, et al.
Publicado: (2021)

Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations
por: Liao, Jiatao, et al.
Publicado: (2021)

Cognitive Impairment in Older Cancer Patients Treated with First-Line Chemotherapy
por: Dos Santos, Mélanie, et al.
Publicado: (2021)

Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review
por: Li, Lingling, et al.
Publicado: (2020)

Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
por: Liu, Lulu, et al.
Publicado: (2023)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021)

Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy
por: Qian, Li, et al.
Publicado: (2021)

Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study
por: Surmont, V., et al.
Publicado: (2009)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first‐line treatment for advanced esophageal cancer
por: Ye, Zhuo‐Miao, et al.
Publicado: (2022)

Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
por: Khan, Iftekhar, et al.
Publicado: (2015)

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
por: Lu, Tingting, et al.
Publicado: (2023)

Neutropenia-Related Costs in Patients Treated with First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Stokes, Michael E., et al.
Publicado: (2009)

Rational application of the first‐line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta‐analysis
por: Cao, Rui, et al.
Publicado: (2019)

Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors combined with chemotherapy in first‐line treatment in an advanced non‐small cell lung cancer patient with EGFR sensitive mutation
por: Huang, Aimi, et al.
Publicado: (2016)

EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer
por: Fang, Shu, et al.
Publicado: (2014)

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy
por: Manegold, Christian, et al.
Publicado: (2017)

Outcomes of 596 Advanced Gastric Cancer Patients with Different Numbers of Chemotherapy Lines: The More Chemotherapy Lines, the Better Survival
por: Sun, Li, et al.
Publicado: (2020)

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
por: Han, Baohui, et al.
Publicado: (2018)

First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
por: Athanassiou, A. E., et al.
Publicado: (1989)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998)

Clinical significance of serum tumor markers for advanced gastric cancer with the first-line chemotherapy
por: Sun, Zhiwei, et al.
Publicado: (2019)

Performances of Prognostic Models in Stratifying Patients with Advanced Gastric Cancer Receiving First-line Chemotherapy: a Validation Study in a Chinese Cohort
por: Xu, Hui, et al.
Publicado: (2021)

Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer
por: Shen, Yan-Wei, et al.
Publicado: (2016)

Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
por: Cappuzzo, F, et al.
Publicado: (2005)

The Role of Monoclonal Antibody in Combination with First-Line Chemotherapy in Asian Patients with Advanced Non-Small Cell Lung Cancer
por: Cho, Byoung Chul, et al.
Publicado: (2010)

Inflammation-related Genetic Variations and Survival for Advanced Non-Small Cell Lung Cancer Receiving First-line Chemotherapy
por: Pu, Xia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6b8nhleaj2586hof8071s2f6t0